EHA 2021 | Impact of splicing factor mutations on AML treatment
Curtis Lachowiez
• 3 Jun 2021
Curtis Lachowiez, MD, MD Anderson Cancer Center, Houston, TX, discusses a recent paper investigating splicing factor mutations in patients with acute myeloid leukemia (AML). These mutations include SRSF2, SF3B1, U2AF1, and ZRSR2. Dr Lachowiez reports that patients with these mutations trend towards inferior outcomes with intensive chemotherapy. Dr Lachowiez also discusses how advances in technology could benefit this field of research. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
